We performed an in vivo screen to identify essential DUBs that may contribute to the acquired chemoresistance of gynecological cancer, and the results revealed JOSD1 to be a key antiapoptotic DUB whose accumulation leads to acquired chemoresistance in both cervical and ovarian cancer. Here, ZUP1 is linked to ovarian carcinoma.